Business Context and Reporting Period
This Form 8-K was filed by Neuralstem, Inc. on April 16, 2014. The report discloses a significant corporate event regarding the company's clinical development program. Note: The metadata provided lists "Palisade Bio, Inc.", but the filing text explicitly identifies the registrant as Neuralstem, Inc.
Key Financial Metrics
This filing is a Current Report (Form 8-K) focused on a specific event and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The material change reported is the regulatory approval of a clinical trial:
- Event: The Institutional Review Board (IRB) of the University of California, San Diego, School of Medicine approved a Phase I safety trial.
- Subject: Treatment of chronic spinal cord injury (cSCI).
- Product: The company's NSI-566 stem cells.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the IRB approval, which enables the commencement of the Phase I safety trial. The filing does not provide specific financial guidance, discuss general business risks, or detail contingencies beyond the standard regulatory process for clinical trials.
Investor Verification Checklist
- Verify the exact scope and design of the Phase I safety trial for NSI-566 in the attached press release (Exhibit 99.01).
- Confirm the timeline for patient enrollment and expected trial duration.
- Review the company's most recent 10-K or 10-Q for current financial status, as this 8-K contains no financial data.
- Monitor future filings for updates on trial initiation and safety data readouts.